Amplia Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Amplia Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.001%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.001%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Jan 13

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Apr 28

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Feb 28

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Jan 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ATX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ATX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Amplia Therapeutics Piyasaya Karşı Temettü Getirisi

ATX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ATX)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (ATX) (3 yıla kadar)	n/a

Önemli Temettü: ATX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ATX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ATX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ATX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Amplia Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.9 million.

Amplia Therapeutics Limited, Annual General Meeting, Aug 23, 2024

New minor risk - Shareholder dilution

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

Amplia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.27 million.

New major risk - Market cap size

Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US

New major risk - Financial position

New major risk - Market cap size

Amplia Therapeutics Limited Announces Chief Financial Officer Changes

New major risk - Market cap size

New major risk - Market cap size

Amplia Therapeutics Limited, Annual General Meeting, Aug 24, 2023

Amplia Receives Grant to Collaborate with CSIRO

Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945

Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022

Amplia Therapeutics Limited Announces CEO Changes

Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer

Amplia Therapeutics Limited, Annual General Meeting, Aug 25, 2022

Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis

Amplia Therapeutics Limited Receives Second Ethics Clearance for Phase 2 Trial

Amplia Therapeutics Limited Receives Human Research Ethics Committee Approval to Initiate Phase 2 Clinical Trial of Its Focal Adhesion Kinase Inhibitor, AMP945

Amplia Therapeutics Limited Completes Manufacture of AMP945 for Planned Trials

We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully

Non-Executive Director recently bought AU$104k worth of stock

Chief Financial Officer Jeff Carter has left the company

Amplia to Conduct Phase 2 Trial in First-Line Pancreatic Cancer Patients

Non-Executive Director recently bought AU$122k worth of stock

Amplia Therapeutics Limited Announces Results from Successful Phase 1 Clinical Trial of Amp945

Amplia Therapeutics Limited Receives New Data from its Collaboration with Professor Paul Timpson of the Garvan Institute of Medical Research, Sydney

Amplia Therapeutics Limited announced that it expects to receive AUD 3.81455 million in funding from Platinum Investment Management Limited, Blueflag Holdings Pty Ltd, Acorn Capital Limited, and other investors

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Amplia Therapeutics Limited Completes Single Dose Study of AMP945

Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings

Amplia Therapeutics Limited Initiates Multiple Dose Study of AMP945

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

New 90-day high: AU$0.22

Amplia Therapeutics Limited Announces First Human Dose in Phase 1 Clinical Trial of AMP945

Amplia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 3.987791 million.

Amplia Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin